Skip to Main Content
Contribute Try STAT+ Today

Agios Pharmaceuticals said Monday that it is selling its cancer business to the French drug maker Servier — a decision that will narrow the biotech’s focus to developing medicines for inherited diseases and enable a shareholder-friendly stock repurchase program.

Servier is paying $1.8 billion in cash for Agios’ entire cancer portfolio, consisting of two approved blood cancer treatments, three experimental drugs in clinical trials, and all associated Agios employees. Agios is also eligible for another $200 million in cash and royalties on future drug sales, if certain conditions are later met.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.